New Safety Data on treatment with COPAXONE(R) (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

New Safety Data on treatment with COPAXONE(R) (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

Publication date: Oct 13, 2021

Al, Safety analysis of offspring breastfed by mothers on glatiramer acetate therapy for relapsing multiple sclerosis; presented at EAN 2021. In new subgroup analyses, 50 offspring from the glatiramer acetate (GA) cohort (49 pregnancies; 49 women) and 50 from the control (50 pregnancies; 50 women) were included. There is historically limited clinical safety data for infants who are breastfed by mothers undergoing treatment for MS including during the pregnancy period. While re-staring DMT during breastfeeding, a mother has concerns whether her exposure to DMT during pregnancy and breastfeeding may harm her child. “The data presentation follows extensive ongoing study of COPAXONE in a variety of real-world settings that seek to improve treatment decision making. Growth parameters (body weight, body length and head circumference) were also comparable between cohorts at birth as well as at each of the other five time points studied. Our mission at Teva is to improve the lives of patients, supporting them with important medicines throughout lifes stages, and during family planning in particular.

Concepts Keywords
Breastfeedingmaternal Http
Canada Multiple sclerosis
Cobra Teva Pharmaceuticals
Sclerosis Breastfeeding
Drugs
Articles
Medicine
Glatiramer acetate

Semantics

Type Source Name
drug DRUGBANK Glatiramer
drug DRUGBANK Acetate ion
disease MESH Multiple Sclerosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *